Form 4: Century Therapeutics CEO Brent Pfeiffenberger Reports Stock Transactions

CEO Brent Pfeiffenberger reports the sale of shares to cover tax obligations and the grant of restricted stock units and stock options.

Summary

• On March 10, 2025, Brent Pfeiffenberger, CEO of Century Therapeutics, sold 2,235 shares of common stock at $0.615 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• On March 11, 2025, Pfeiffenberger was granted 521,500 restricted stock units (RSUs) and a stock option to purchase 521,500 shares at an exercise price of $0.601.
• Following these transactions, Pfeiffenberger beneficially owns 1,711,810 shares of Century Therapeutics common stock and 521,500 stock options.
• The RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock options vest 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports stock transactions by the CEO, which are a normal part of executive compensation. The vesting schedules suggest a positive outlook, but the sale of shares could be viewed with slight caution.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with the long-term success of the company.
• The vesting schedules for the RSUs and stock options incentivize continued service and commitment from the CEO.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it is a common practice.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Century Therapeutics' stock.
• The vesting of the RSUs and stock options is contingent on the CEO's continued service, creating a potential risk if he were to leave the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest an expectation of continued growth and success for Century Therapeutics.

Industry Context

Stock transactions by company executives are common and closely monitored by investors as they can provide insights into management's confidence in the company's future prospects. The granting of RSUs and stock options is a typical form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include a mix of salary, stock options, and restricted stock units.
• Vesting schedules are typically structured to incentivize long-term performance and retention.
• The specific terms of Pfeiffenberger's compensation package would need to be compared to those of CEOs at similarly sized and staged biotechnology companies to determine if they are in line with industry standards.

Stakeholder Impact

• Shareholders may be interested in the CEO's stock transactions as an indicator of his confidence in the company.
• Employees may be affected by the CEO's continued service, which is tied to the vesting of his RSUs and stock options.

Key Dates